Dublin, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The "Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. Growth in the ...
Bevirimat, first maturation inhibitor: tablet formulation provides lower than expected plasma levels
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Alkahest, a California-based biotech start-up, has just revealed some compelling early results from an ongoing Phase 2 trial into the efficacy of its novel formulation of plasma proteins derived from ...
Please provide your email address to receive an email when new articles are posted on . The use of platelet-rich plasma remains controversial as treatment regimens and formula concentrations are not ...
Though much has been made of treatment involving platelet-rich plasma – from efficacy to formulations, hype, uses and potential – relatively little data exists to firmly support or refute its ...
Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies. Takeda ...
old man in hospital bed A novel oral formulation of urea increased plasma sodium levels significantly and was well tolerated, according to investigators. Urea appears to be a safe and effective ...
The global Plasma-derived Factor VIII Market was valued at US$ 8263.2 million in 2023 and is projected to reach US$ 12420 million by 2030, at a CAGR of 6.0% during the forecast period. The Plasma ...
A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback